Mitsubishi starts Ph II/III of fasinumab to treat OA

Mitsubishi Tanabe Pharma Corp. (Tokyo:4508) began the Phase II/III J01 trial of fasinumab (REGN475, MT-5547) to treat osteoarthritis (OA). The

Read the full 202 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE